Monoclonal Antibody to Kidney Injury Molecule 1 (Kim1)
| Code | Size | Price |
|---|
| MAA785Ra21-20ul | 20ul | £89.00 |
Quantity:
| MAA785Ra21-100ul | 100ul | £166.00 |
Quantity:
| MAA785Ra21-200ul | 200ul | £224.00 |
Quantity:
| MAA785Ra21-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
HAVCR1; TIM1; TIMD1; HAVCR; Hepatitis A Virus Cellular Receptor 1; T Cell Immunoglobulin And Mucin Domain-Containing Protein 1; T-cell immunoglobulin mucin receptor 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Kidney Injury Molecule 1
Potency (Clone Number):
C8
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
References
https://sciencedirect.53yu.com/science/article/pii/S0925443922002939; https://www.mdpi.com/1422-0067/23/23/15224;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Kidney Injury Molecule 1 (Kim1) | RPA785Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||